The AI Secret Nobody Sees Coming

You probably never heard of... [Energy and Capital Header] Practical Investment Analysis for the New Energy Economy The AI Secret Nobody Sees Coming Keith Kohl | Nov 02, 2023 You probably have never heard of Friedrich Wilhelm Adam Sertürner. Don’t beat yourself up too bad if the name doesn’t ring a bell. Because very few people have heard of this name. Yet Sertürner holds an interesting place in the history of medicine. Sertürner was a pharmacist's assistant living in the south of lower Saxony in Germany at the beginning of the 19th century. Throughout his years as an assistant, and later as a pharmacist, he worked on a new method of isolating morphine from opium. You could hardly call his early work a success. Not only was he using an impure alcoholic extract of opium, but he was also testing on stray dogs, mice, and on occasion… himself. In fact, it took more than 11 years before he was able to extract crystals of pure morphine through precipitation. This was the first notable moment in human drug discovery. This Pill Will “Define the Next Decade” A new medical breakthrough smaller than the size of your pinkie is about to reshape human history. Because believe it or not, this tiny pill can eradicate every single sign and symptom of aging and disease... Which leaves you looking and feeling forever young. Don’t believe it? [Check out this proof...]( Historically, scientists would either identify an active ingredient from a traditional remedy, or through sheer blind luck. Perhaps the most famous example that comes to mind took place in 1928. After coming back from vacation, Alexander Fleming discovered mold growing on his petri dish in his lab. [eac image 1] Interestingly, the mold was preventing the staphylococcus bacteria from growing around it, and thus penicillin was discovered. What you may not realize, however, is that Fleming’s discovery of penicillin was shrugged off by his peers at the time. It was written off as a freak occurrence. Because no matter how much they tried, they couldn’t purify penicillin, and thus was regarded as more of a curiosity by the scientific community. It took another ten years before two scientists, Ernst Chain and Howard Florey, formed a team to systematically produce a pure form of penicillin. Then, it took another three years after that before the “Penicillin Project” became a success. More than 80 years later, the drug discovery process is still plagued by two huge obstacles: Time and money. But that’s all about to change… The No. 1 AI Stock of Our Era Using artificial intelligence (AI), this obscure company has made what could arguably be the most impactful medical breakthrough of our lifetime... Reducing the time frame for drug discovery by 70%... Slashing the costs of drugs by 80%... And even leading the charge with a novel cancer treatment that's swiftly advancing through clinical trials! This firm, with its innovative use of AI, is the catalyst of what Morgan Stanley says is a "$50 billion opportunity" for investors. It’s precisely why big market players like Bill Gates, BlackRock, and Citigroup are heavily investing in this $5 stock. [Join them before it’s too late.]( Despite all the advancements we’ve made in the past century, you would be shocked at the numbers. I know it’s easy to denigrate Big Pharma in today’s society. Like Big Oil, they’re an easy scapegoat; sometimes that blame is deserved, but sometimes it's not. From discovery to approval, it can take a company up to 20 years and cost tens of billions of dollars to bring a new drug to market. In 2019 alone, the pharmaceutical industry spent $83 billion on research and development. If that sounds bleak, just remember that 90% of potential drug candidates that make it to clinical trials fail to make it through the approval process. But that entire process is about to be turned upside down due to this technology. And I know all of my readers have come across this technology over the last two years: Artificial Intelligence. AI-assisted drug discovery may sound like something out of science fiction, but it’s far closer to reality than you might first think. We’re far beyond chatting on OpenAI, Google’s Bard, or creating some fascinating AI images using Midjourney. Through the use of certain AI systems, scientists can greatly increase target identification during the drug discovery phase, run simulations that would reduce the need for physical testing, utilize its algorithms to prioritize potential molecules and even generate synthesis pathways for manufacturing these compounds. This is beyond game-changing. Thing is, this technology is still in its infancy. That means there are only a few players in the AI drug discovery race. Once this is successful, it’ll be one of the most groundbreaking opportunities in the biotech sector.  I strongly recommend you take just a few minutes out of your day and [check out all the details in this]([investment presentation.Â]( [The next step is up to you](. Until next time, [Keith Kohl Signature] Keith Kohl Keith connects with hundreds of thousands of readers as the Managing Editor of [Energy & Capital](, as well as the investment director of Angel Publishing's [Energy Investor]( and [Technology and Opportunity](. [youtube logo]( [Angelpub ARE site logo 100x100]@AngelInvestmentResearch Top 10 Stocks to Own for November 2023 |The Wealth Advisory Top 10 Tune in for the Top 10 Stocks to Own for November 2023 from Jason Williams and Jason Simpkins of The Wealth Advisory! In this special clip from The Wealth Advisory's monthly series "TWA's Top 10 Stocks to Own," Jason Williams and Jason Simpkins break down the ten best stocks to own for November 2023. It takes quite the expert to possess that range of financial literacy. It also takes quite the expert to help you learn, and help you EARN. That’s why we created The Wealth Advisory. Whether you’ve already retired, are a few years away, or have decades to invest...  [top nuclear stocks to buy now](       [Fb]( [Li]( [Tw]( This email was sent to {EMAIL}. You can manage your subscription and get our privacy policy [here](. Energy and Capital, Copyright © 3 East Read Street, Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info [here]( including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at [1-877-303-4529](tel:/18773034529).